Angiotensin receptor blockers and diuretics as combination therapy: Clinical implications

American Journal of Hypertension

Volumn 17, Issue 3, 2004, Pages 277-280

  Ram, C Venkata S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; IMIDAZOLES; RECEPTORS, ANGIOTENSIN; SODIUM CHLORIDE SYMPORTER INHIBITORS; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME;

EID: 1442299288     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.09.002     Document Type: Editorial

References (27)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
2. Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R: Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995;155:1757-1762
3. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675.
4. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
5. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
6. Izzo J.L. Jr. Systolic hypertension, arterial stiffness, and vascular damage role of the renin-angiotensin system. Blood Press Monit. 5:(Suppl 2):2000;S7-S11.
7. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 89:2002;3A-10A.
8. Greathouse M. A review of olmesartan medoxomil monotherapy antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? Congest Heart Fall. 8:2002;313-320.
9. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 103:2001;904-912.
10. Chung O, Csikos T, Unger T: Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens 1999;13(Suppl 1):S11-S20; discussion S33-S34
11. Birkenhager W.H., de Leeuw P.W. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens. 17:1999;873-881.
12. Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 14:(Suppl 1):2000;S73-S86.
13. Goodfriend T.L., Elliott M.E., Catt K.J. Angiotensin receptors and their antagonists. N Engl J Med 20. 334:1996;1649-1654.
14. Grossman E., Messerli F.H., Neutel J.M. Angiotensin II receptor blockers equal or preferred substitutes for ACE inhibitors? Arch Intern Med 10. 160:2000;1905-1911.
15. Neutel J.M. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 19. 87:2001;37C-43C.
16. Smith D.H. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. Am J Hypertens. 15:2002;108S-114S.
17. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., Konstam M.A., Riegger G., Klinger G.H., Neaton J., Sharma D., Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 6. 355:2000;1582-1587.
18. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 7. 360:2002;752-760.
19. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 23 2002;359:995-1003
20. Kaplan N.M. Kaplan's Clinical Hypertension. 8th ed :2002;Lippincott Williams & Wilkins, Philadelphia.
21. Chrysant S.G., Weber M.A., Wang A.C., Hinman D.J. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 17:2004;252-259.
22. Conlin P.R., Spence J.D., Williams B., Ribeiro A.B., Saito I., Benedict C., Bunt A.M. Angiotensin II antagonists for hypertension are there differences in efficacy? Am J Hypertens. 13:2000;418-426.
23. Cohen J.D. Abnormal electrocardiograms and cardiovascular risk role of silent myocardial ischemia. Evidence from MRFIT. Am J Cardiol. 70:1992;14F-18F.
24. Girola S.S., Mazzone A., Moroni M., Porta C., Nastasi G., Notario A. Hypokalemic rhabdomyolysis and thiazide diuretics. 3 clinical cases. Ann Ital Med Int. 10:1995;134-137.
25. Langtry H.D., McClellan K.J. Valsartan/hydrochlorothiazide. Drugs. 57:1999;751-758.
26. Wellington K., Faulds D.M. Valsartan/hydrochlorothiazide a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs. 62:2002;1983-2005.
27. Benz J.R., Black H.R., Graff A., Reed A., Fitzsimmons S., Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 12:1998;861-866.